BioNexus Gene Lab Corp.
NasdaqCM:BGLC Rapport sur les actions
Capitalisation boursière : US$6.3m
BioNexus Gene Lab Bilan de santé
Santé financière contrôle des critères 5/6 BioNexus Gene Lab possède un total de capitaux propres de $9.5M et une dette totale de $215.5K, ce qui porte son ratio d'endettement à 2.3%. Son actif total et son passif total sont $11.1M et de $1.6M.
Informations clés Ratio de couverture des intérêts n/a Argent liquide US$5.41m Fonds propres US$9.55m Total du passif US$1.59m Total des actifs US$11.14m
Mises à jour récentes de la santé financière
BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting Determination Nov 09
The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2) May 10 BioNexus Gene Lab Corp. announced delayed annual 10-K filing Mar 29
BioNexus Gene Lab Corp. announced delayed 10-Q filing Nov 15
BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2) Nov 14 BioNexus Gene Lab Corporation announced delayed annual 10-K filing Apr 03
Afficher toutes les mises à jour
BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting Determination Nov 09
Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating Committee Oct 18 BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024 Sep 10
Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023) Aug 16
High number of new and inexperienced directors Jun 28
The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2) May 10 BioNexus Gene Lab Corp. announced delayed annual 10-K filing Mar 29
BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks Reasonable Feb 14
High number of new and inexperienced directors Feb 14 Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp Jan 17
BioNexus Gene Lab Corp. announced delayed 10-Q filing Nov 15
BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2) Nov 14
High number of new and inexperienced directors Nov 14 BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer
BioNexus Gene Lab Corp. Announces Executive Changes Sep 09
New major risk - Revenue and earnings growth Aug 17
Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022) Aug 17
New minor risk - Shareholder dilution Jul 26
High number of new and inexperienced directors Jul 21
BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million. Feb 16 Bionexus Gene Lab Corporation Announces Management Changes BioNexus Gene Lab Corporation announced delayed annual 10-K filing Apr 03
BioNexus Gene Lab Corporation announced delayed 10-Q filing May 18
BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd. Jan 01
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de BGLC ( $7.8M ) dépassent ses passifs à court terme ( $1.4M ).
Passif à long terme: Les actifs à court terme de BGLC ( $7.8M ) dépassent ses passifs à long terme ( $194.6K ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: BGLC dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de BGLC est passé de 0% à 2.3% au cours des 5 dernières années.
Analyse des pistes de trésorerie Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: BGLC dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: BGLC dispose d'une marge de trésorerie suffisante pour 1.3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 16.1 % chaque année.
Découvrir des entreprises saines Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
